Authors : Claire G. Beringuela; Dianna Jhent S. Cullamar; Levy Donor; Czedrick Khien S. Mongaya; Gecelene C. Estorico

Volume/Issue : Volume 9 - 2024, Issue 11 - November

Google Scholar : https://tinyurl.com/3r4efd6y

Scribd : https://tinyurl.com/2e9h2npd

DOI : https://doi.org/10.38124/ijisrt/IJISRT24NOV618

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : The SARS-CoV-2 pandemic has necessitated the rapid development and deployment of effective vaccines. This systematic review included articles published between 2019 and 2024 that focused on comparing the different vaccines against SARS-CoV-2 and its two variants: omicron and delta. Articles and scientific papers were selected based on originality, full- text availability, and English language. Excluded were case studies, reviews without data, or articles lacking full text or English translation. All relevant studies were systematically selected from Google Scholar, ResearchGate, Elsevier, Springer, and Academia.edu to identify relevant research exploring the six selected vaccines. The collected review utilized and identified a total of 33 studies. The researchers were able to use 17 of these studies for a more in-depth quantitative analysis. The qualitative analysis of all 16 studies revealed that pain and swelling in the injection area, headache, muscle pain, and fatigue are the most frequently observed side effects of vaccines on humans. This systematic review aims to comprehensively compare the efficacy of the vaccines and their side effects and their efficacy rate to omicron and delta variants. By conducting a rigorous analysis of existing literature, the researchers evaluate the efficacy of the vaccines and how they respond to omicron and delta variants when it comes to efficacy as well. The review will focus on key outcomes such as doses and frequencies, vaccine efficacy based on Phase III clinical trials, and side effects. Understanding the comparative strengths and limitations of different vaccines will inform public health and optimize vaccination strategies to mitigate the ongoing pandemic.

Keywords : Boosters, Efficacy, Vaccine, Variants, Virus.

References :

1. Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., ... & Lopez Bernal, J. (2022). Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant. New England Journal of Medicine, 386(16), 1532-1546. DOI: 10.1056/NEJMoa211945   
2. Bartsch, S. M., O’Shea, K. J., Ferguson, M. C., et al. (2020). Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention. American Journal of Preventive Medicine, 59(4), 493–503. https://doi.org/10.1016/j.amepre.2020.06.011  
3. Bernal, J. L., Andrews, N., Gower, C., et al. (2021). Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ, n1088. https://doi.org/10.1136/bmj.n1088  
4. Cababan, M. A. L., Catane, G. V., & Alava, W. G. (2021). Covid-19 Vaccines in the Philippines: A Meta-analysis. Health Econ, 7(7), 179. doi: 10.35248/2471-268x.21.7.  
5. Cai, C., Peng, Y., Shen, E., et al. (2021). A comprehensive analysis of the efficacy and safety of COVID-19 vaccines. Molecular Therapy, 29(9), 2794–2805. https://doi.org/10.1016/j.ymthe.2021.08.001   
6. Chohan, H. K., Jamal, A., Mubeen, M., et al. (2023). The Common Systemic and Local Adverse Effects of the Sinovac COVID-19 Vaccine: An Observational Study From Pakistan. Cureus, 15(5). https://doi.org/10.7759/cureus.38564  
7. Ciotti, M., Ciccozzi, M., Terrinoni, A., Jiang, W., Wang, C., & Bernardini, S. (2020). The COVID-19 pandemic. Critical Reviews in Clinical Laboratory Sciences, 57(6), 365–388. https://doi.org/10.1080/10408363.2020.1783198  
8. COVID-19 vaccines. (2023, October 19). https://www.who.int/westernpacific/emergencies/covid-19/covid-19-vaccines  
9. Deplanque, D., & Launay, O. (2021). Efficacy of COVID-19 vaccines: From clinical trials to real life. Therapies, 76(4), 277–283. https://doi.org/10.1016/j.therap.2021.05.004  
10. Different types of COVID-19 vaccines: How they work. (2024,September 7). Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/different-types-of-covid-19-vaccines/art-20506465  
11. Doroftei, B., Ciobica, A., Ilie, O., et al. (2021). Mini-Review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics, 11(4), 579. https://doi.org/10.3390/diagnostics11040579 
12. Gomes, I. A., Soares, P., Rocha, J. V., Gama, A., Laires, P. A., Moniz, M., ... & Nunes, C. (2022). Factors associated with COVID-19 vaccine hesitancy after implementation of a mass vaccination campaign. Vaccines, 10(2), 281. https://doi.org/10.3390/vaccines10020281 
13. Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., ... & Alroy-Preis, S. (2021). Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet, 397(10287), 1819-1829. . DOI: 10.1016/S0140-6736(21)00947-8 
14. Hahn, W. O., & Wiley, Z. (2022). COVID-19 vaccines. Infectious Disease Clinics of North America, 36(2), 481. doi: 10.1016/j.idc.2022.01.008   
15. Hu, B., Guo, H., Zhou, P., & Shi, Z. (2020). Characteristics of SARS-COV-2 and COVID-19. Nature Reviews Microbiology, 19(3), 141-154. https://www.nature.com/articles/s41579-020-00459-7  
16. Huang, Z., Su, Y., Zhang, T. et al. A review of the safety and efficacy of current COVID-19 vaccines. Front. Med. 16, 39–55 (2022). https://doi.org/10.1007/s11684-021-0893-y 
17. Iacobucci, G. (2021). Covid-19: Two doses of Pfizer vaccine are “highly effective” against infection, hospital admission, and death, study finds.. https://doi.org/10.1136/bmj.n1164  
18. IKezia, V. A. L. E. R. I. E., & Ramatillah, D. L. (2022). Intensive monitroing of sinovac vaccine for safety and efficacy among Indonesian population. Int. J. Appl. Pharm, 14, 44-48. DOI: https://dx.doi.org/10.22159/ijap.2022.v14s2.44748  
19. Katella, K. (2024, September 3). Comparing the COVID-19 vaccines: How are they different? Yale Medicine. https://www.yalemedicine.org/news/covid-19-vaccine-comparison  
20. Kaznadzey, A., Tutukina, M., Bessonova, T., Kireeva, M., & Mazo, I. (2022). BNT162b2, mRNA-1273, and Sputnik V vaccines induce comparable immune responses on a par with severe course of COVID-19. Frontiers in Immunology, 13, 797918. doi: 10.3389/fimmu.2022.797918  
21. Kim, J.H., Marks, F. & Clemens, J.D. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med 27, 205–211 (2021). https://doi.org/10.1038/s41591-021-01230-y  
22. Krammer, F. (2020). SARS-CoV-2 vaccines in development. Nature, 586(7830), 516–527. https://doi.org/10.1038/s41586-020-2798-3  
23. Li, X. N., Huang, Y., Wang, W., Jing, Q. L., Zhang, C. H., Qin, P. Z., ... & Zhong, N. S. (2021). Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case–control real-world study. Emerging microbes & infections, 10(1), 1751-1759. https://doi.org/10.1080/22221751.2021.1969291 
24. Mahor, H., Mukherjee, A., Sarkar, A., & Saha, B. (2023). Anti-leishmanial therapy: Caught between drugs and immune targets. Experimental Parasitology, 245, 108441. https://doi.org/10.1016/j.exppara.2022.108441 
25. Meo, S. A., Bukhari, I. A., Akram, J., Meo, A. S., & Klonoff, D. C. (2021). COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. European Review for Medical & Pharmacological Sciences, 25(3).DOI: 10.26355/eurrev_202102_24877 
26. Moghadas, S. M., Vilches, T. N., Zhang, K., et al. (2021). The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States. Clinical Infectious Diseases, 73(12), 2257–2264. https://doi.org/10.1093/cid/ciab079  
27. Philippines – COVID19 vaccine tracker. (n.d.). https://covid19.trackvaccines.org/country/philippines/  
28. Reynolds, L., Dewey, C., Asfour, G., et al. (2023). Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review. Frontiers in Public Health, 11. https://doi.org/10.3389/fpubh.2023.1229716  
29. Ripabelli, G., Tamburro, M., Buccieri, N. et al. Active Surveillance of Adverse Events in Healthcare Workers Recipients After Vaccination with COVID-19 BNT162b2 Vaccine (Pfizer-BioNTech, Comirnaty): A Cross-Sectional Study. J Community Health 47, 211–225 (2022). https://doi.org/10.1007/s10900-021-01039-3  
30. Tavilani, A., Abbasi, E., Ara, F. K., et al. (2021). COVID-19 vaccines: Current evidence and considerations. Metabolism Open, 12, 100124. https://doi.org/10.1016/j.metop.2021.100124  
31. Tigas, K.A. (2021). Storage and Dosage Requirements, Efficacy, Safety, and Adverse Effects of 6 COVID-19 Vaccines: A Comparative Analysis. https://doi.org/10.13140/RG.2.2.10023.36001. 
32. Yin, Y., Li, X., Qian, C., Cheng, B., Lu, F., & Shen, T. (2022). Antibody efficacy of inactivated vaccine boosters (CoronaVac) against Omicron variant from a 15-month follow-up study. The Journal of Infection, 85(4), e119. doi: 10.1016/j.jinf.2022.06.018 
33. Radhakrishnan, N., Liu, M., Idowu, B., et al. (2023). Comparison of the clinical characteristics of SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) infected patients from a single hospitalist service. BMC Infectious Diseases, 23(1). https://doi.org/10.1186/s12879-023-08714-x  
34. Katella, K. (2023, September 1). Omicron, Delta, Alpha, and more: What to know about the coronavirus variants. Yale Medicine. https://www.yalemedicine.org/news/covid-19-variants-of-concern-omicron  
35. Gbaguidi, G. N., Aubert, L., Schaeffer, J., et al. (2023). Emergence and Evolution of the Omicron SARS-CoV-2  Variant in the Island of Martiniqque. Infectious Diseases Now, 53 (4), 104690. https://doi.org/10.1016/j.idnow.2023.104690